Originally published in The Forefront, May 10, 2019
A new therapy to re-engage the heart’s natural electrical pathways – instead of bypassing them – could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University of Chicago Medicine.
In a first-ever pilot study, called the His SYNC trial, researchers compared the effectiveness of two different cardiac resynchronization therapies, or treatments to correct irregularities in the heartbeat through implanted pacemakers and defibrillators. The current standard of care, known as biventricular pacing, uses two pacing impulses in both lower chambers, whereas the newer approach, called His bundle pacing, attempts to work toward engaging and restoring the heart’s natural physiology. The two approaches have never before been directly compared in a head-to-head clinical trial.